PPA
ARCT icon

Parametric Portfolio Associates’s Arcturus Therapeutics ARCT Stock Holding History

Parametric Portfolio Associates’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,135
Closed -$486K – 3676
2021
Q4 		$486K Sell
13,135
-11,640
-47% -$474K ﹤0.01% 3083
2021
Q3 		$1.18M Buy
24,775
+14,619
+144% +$655K ﹤0.01% 2725
2021
Q2 		$344K Sell
10,156
-1,181
-10% -$40K ﹤0.01% 3225
2021
Q1 		$468K Buy
11,337
+4,128
+57% +$246K ﹤0.01% 3527
2020
Q4 		$313K Buy
+7,209
New +$488K ﹤0.01% 3581

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parametric Portfolio Associates's ARCT Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Arcturus Therapeutics (ARCT) in Q1 2022, closing a stake of 13,135 shares — an estimated $486K sold.

Parametric Portfolio Associates first reported a position in ARCT in Q4 2020 and held it in 5 quarters. The position peaked at $1.18M in Q3 2021. 130 funds tracked by Wall St. Rank hold ARCT as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Arcturus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 13,135 Arcturus Therapeutics shares in Q1 2022, an estimated $486K.
  • Parametric Portfolio Associates first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 5 quarters.
  • Parametric Portfolio Associates's Arcturus Therapeutics position peaked at $1.18M in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.